Regulation
Editors’ Briefing: On Our Radar This Week (Feb. 10–Feb. 17)
This week in political economy.
Yesterday's New York Times editorial: “The terror that has gripped their elected officials … is fear of the wealthy gun...
Editors’ Briefing: On Our Radar This Week (Feb. 2–Feb. 10)
This week in political economy.
India’s competition authority imposed a 1.36 billion rupees ($21.1 million) fine on Google after it found the company guilty...
How Regulation Subsidizes Big Finance
If you want to understand how the US economy is producing big gains for those at the top and stagnation for everybody else, the...
The Secret Driver of US Health Care Costs: Politicians Wanting to Get Reelected
A pioneering new study provides a first-of-its-kind look into the outsized effect that lobbying and political maneuverings have on health care spending.
Americans spend significantly more...
Will Repeal of Net Neutrality Accelerate the Trend in Media Consolidation? The History of Cable Suggests "Yes"
The history of cable and cable programming strongly suggests that without specific FCC safeguards, we can expect a massive “arms race” by providers to...
Stigler on Monopolies: “Competition is a Tough Weed, Not a Delicate Flower”
Many of Stigler’s views on monopoly and antitrust were consistent through the decades. Even after his concerns of monopoly began to recede, he continued...
George Stigler on Regulation: Lessons for Today
October 20 marks the 35th anniversary of George Stigler’s Nobel prize, the first of Booth School of Business’s grand total of eight Nobels. To...
Who Is to Blame for the 2008 Financial Crisis?
The IGM Center at the University of Chicago has asked its American and European economist panel to rate the main causes of the financial...
Eliot Spitzer: The Democratic Party Has Become the Party of the Status Quo
Former New York governor Eliot Spitzer talks about antitrust, digital platforms, economic concentration, and regulatory capture. Part 2 of 2.
In the first part of...
"The Pharmaceutical Industry Has a Large Amount of Control Over the Field of Oncology"
In the second part of our two-part interview with Daniel Goldstein, MD, an oncologist who studies the influence of business interests on healthcare, we talk...
